TYP — Material Events
ASX:TYP · 9 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Tryp Secures $6.1m to Accelerate Psilocin Drug Trials for Binge Eating DisorderMedium
Tryptamine Therapeutics raises $6.1m to fast-track TRP-8803 clinical development
5 Nov 2025
·Capital Raising
·85
Tryp Teams with Top Neuroscientists to Pioneer EEG Brain Entropy BiomarkerMedium
Tryptamine Therapeutics partners with leading neuroscientists to develop EEG brain entropy biomarker for psychedelic drug TRP-8803
21 Aug 2025
·ASX Release
·85
Tryptamine Therapeutics Advances Psychedelic Trials Amid $5.3M Loss and Board OverhaulMedium
Tryptamine Therapeutics advances clinical trials with $5.3M loss, strengthens Board and funding
29 Aug 2025
·Appendix 4E and Annual Report
·85
Tryptamine Therapeutics Launches Groundbreaking Trial for Binge Eating DisorderMedium
Tryptamine Therapeutics launches first clinical trial for BED treatment with TRP-8803, appoints new Chairman
31 July 2025
·Quarterly Activities Report
·85
Tryptamine Therapeutics Launches World-First Trial for Binge Eating DisorderMedium
Tryptamine Therapeutics advances TRP-8803 BED trial, secures funding and landmark biomarker collaboration
31 Oct 2025
·Quarterly Activities Report
·85
Tryptamine Therapeutics Enrolls First Patient in Groundbreaking BED TrialMedium
Tryptamine Therapeutics Enrolls First Patient in Pioneering IV Psilocin Trial for Binge Eating Disorder
14 Oct 2025
·Clinical Trial Update
·85
Tryptamine Therapeutics Launches Groundbreaking IV Psilocin Trial for Binge Eating DisorderMedium
Tryptamine Therapeutics begins patient recruitment for pioneering IV psilocin trial to treat Binge Eating Disorder
21 July 2025
·Clinical Trial Update
·80
Tryptamine Therapeutics Advances Psychedelic Therapy with Second BED Patient EnrolledMedium
Tryptamine Therapeutics enrolls second patient, schedules first dosing in pioneering BED trial
18 Nov 2025
·Clinical Trial Update
·80
Tryptamine Therapeutics Secures $2.6m to Accelerate TRP-8803 TrialsMedium
Tryptamine Therapeutics secures $2.6m non-dilutive capital to fast-track TRP-8803 clinical trials
12 Aug 2025
·Capital Raising
·75
No articles in this tier for the last 12 months.